Here is a brief follow-up on the question TPM Reader MA addresses in an earlier post: why does the Trump administration have it in for biomedical/disease research? It’s a really good question and one I have not seen an adequate explanation for. But having been reporting on this for a few months now I think I do get the outlines of it.
Want to keep reading?
Join TPM to get full-access to our reporting, newsletters, and other member-only features.